Want to see GB:IMM full AI Analyst Report?
Top Page
ImmuPharma
(LSE:IMM)
Select Model
Select Model
Rating:44Neutral
Price Target:
3.00 p
▼(-14.29% Downside)
Action:Reiterated
Date:09/30/26
The score is driven primarily by weak financial performance—minimal revenue, widening losses, and ongoing negative free cash flow that indicates reliance on external funding—partially offset by low leverage and improved equity. Technicals add pressure as the stock trades below key moving averages with negative MACD. Valuation offers limited support because the negative P/E reflects continued unprofitability and no dividend yield is available.
Positive Factors
Low financial leverage
A balance sheet with little or no debt reduces mandatory financing costs and default exposure while preserving flexibility for research investment. This gives ImmuPharma more room to pursue clinical development or partnerships without the additional pressure that high leverage would create.
Negative Factors
Minimal revenue and widening losses
The absence of a meaningful revenue base leaves the company dependent on future clinical or partnering outcomes to establish commercial economics. Widening losses show that current spending is not yet supported by operating income, increasing the time and execution required to reach sustainability.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage
A balance sheet with little or no debt reduces mandatory financing costs and default exposure while preserving flexibility for research investment. This gives ImmuPharma more room to pursue clinical development or partnerships without the additional pressure that high leverage would create.
Read all positive factors
ImmuPharma (IMM) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£20.59M
Dividend Yield17.86%
Average Volume (3M)1.64M
Price to Earnings (P/E)―
Beta (1Y)0.99
Revenue GrowthN/A
EPS Growth5.62%
CountryUK
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.01
Shares Outstanding623,911,400
10 Day Avg. Volume1,462,100
30 Day Avg. Volume1,641,024
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)44.28
Price to Sales (P/S)0.00
P/FCF Ratio-12.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ImmuPharma Business Overview & Revenue Model
Company Description
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company’s lea...
How the Company Makes Money
ImmuPharma’s business model is primarily based on developing pharmaceutical assets and monetizing them through transactions such as licensing, co-development agreements, and/or commercialization partnerships, rather than operating a large, fully i...
ImmuPharma Financial Statement Overview
Summary
Income Statement
10
Very Negative
Balance Sheet
52
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 118.35K |
| Gross Profit | -7.27K | -35.30K | -63.88K | -37.61K | -118.00K | 118.35K |
| EBITDA | -3.55M | -2.51M | -2.61M | -3.02M | -2.91M | -8.70M |
| Net Income | -7.02M | -1.81M | -2.48M | -2.92M | -3.81M | -8.17M |
Balance Sheet | ||||||
| Total Assets | 3.10M | 1.88M | 977.01K | 2.72M | 3.97M | 6.00M |
| Cash, Cash Equivalents and Short-Term Investments | 695.84K | 1.35M | 236.90K | 208.48K | 667.81K | 1.65M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 111.00 | 700.00 |
| Total Liabilities | 1.28M | 1.19M | 1.52M | 1.67M | 1.45M | 1.58M |
| Stockholders Equity | 1.82M | 686.86K | -542.86K | 1.06M | 2.52M | 4.41M |
Cash Flow | ||||||
| Free Cash Flow | -2.77M | -2.37M | -1.77M | -1.36M | -2.45M | -4.88M |
| Operating Cash Flow | -2.76M | -2.37M | -1.77M | -1.36M | -2.35M | -4.83M |
| Investing Cash Flow | 3.96K | 6.91K | 1.29M | 188.76K | -77.42K | -50.28K |
| Financing Cash Flow | 3.05M | 3.43M | 500.02K | 722.10K | 1.55M | 702.05K |
ImmuPharma Technical Analysis
Negative
3.50
Price Trends
3.73
Negative
3.97
Negative
4.99
Negative
Market Momentum
-0.11
Positive
45.88
Neutral
19.44
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:IMM, the sentiment is Negative. The current price of 3.5 is below the 20-day moving average (MA) of 3.56, below the 50-day MA of 3.73, and below the 200-day MA of 4.99, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 45.88 is Neutral, neither overbought nor oversold. The STOCH value of 19.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:IMM.
ImmuPharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | £15.55M | -31.94 | -5.25% | ― | 95.16% | 85.60% | |
53 Neutral | £115.16M | -17.74 | 90.29% | ― | ― | 69.01% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | £54.81M | -8.97 | -71.28% | ― | ― | 31.58% | |
49 Neutral | £44.83M | -3.87 | -409.57% | ― | ― | 18.57% | |
47 Neutral | £41.92M | -8.10 | -284.01% | ― | ― | -105.65% | |
44 Neutral | £20.59M | -2.62 | -559.87% | 17.86% | ― | 5.62% |
* Healthcare Sector Average
GB:IMM
ImmuPharma
3.28
-7.82
-70.50%
GB:SAR
Sareum Holdings
29.50
6.00
25.53%
GB:SCLP
Scancell Holdings
9.40
-0.35
-3.59%
GB:HEMO
HemoGenyx Pharmaceuticals Plc
700.00
-465.00
-39.91%
GB:SBTX
SkinBioTherapeutics
5.75
-9.13
-61.34%
GB:POLB
Poolbeg Pharma Ltd.
7.00
3.60
105.88%
ImmuPharma Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
ImmuPharma Advances Global Patent Strategy for P140 Autoimmune Precision Therapy
Positive
Sep 15, 2026
ImmuPharma has filed an international Patent Cooperation Treaty application for its P140 precision medicine approach in autoimmune disease, specifically addressing patients with the Type M immune profile who show an enhanced likelihood of response...
Business Operations and Strategy
ImmuPharma’s P140 Shows Promise in Preclinical MASH Study
Positive
Sep 15, 2026
ImmuPharma has announced new peer‑reviewed research showing its peptide P140 demonstrates biological activity in a preclinical model of metabolic dysfunction‑associated steatohepatitis, a liver disease marked by inflammation and fibros...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
ImmuPharma narrows operating loss as fundraising funds P140 and Kapiglucagon push
Positive
Sep 15, 2026
ImmuPharma reported an operating loss of £1.1 million for the six months to 30 June 2026, broadly in line with the prior year, while a non-cash finance loss tied to revaluation of a derivative asset widened the overall loss to £4.7 milli...
Business Operations and StrategyProduct-Related Announcements
ImmuPharma taps Kymos as bioanalytical partner to advance Kapiglucagon diabetes programme
Positive
Aug 10, 2026
ImmuPharma has appointed Kymos Group as the bioanalytical contract research partner for its Kapiglucagon programme, following a competitive tender, marking another key milestone in the drug’s non-clinical and early clinical development. The ...
Business Operations and StrategyProduct-Related Announcements
ImmuPharma Taps Thermo Fisher as CDMO for Kapiglucagon Diabetes Program
Positive
Jul 22, 2026
ImmuPharma has selected Thermo Fisher Scientific’s Patheon pharma services as the contract development and manufacturing organisation for drug product work on its Kapiglucagon program. The appointment follows the earlier choice of Bachem AG ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.